Literature DB >> 29897452

Pre-clinical symptoms of SBMA may not be androgen-dependent: implications from two SBMA mouse models.

Youfen Xu1, Katherine Halievski1, Masahisa Katsuno2, Hiroaki Adachi3, Gen Sobue2, S Marc Breedlove1, Cynthia L Jordan1.   

Abstract

A distinguishing aspect of spinal and bulbar muscular atrophy (SBMA) is its androgen-dependence, possibly explaining why only males are clinically affected. This disease, which impairs neuromuscular function, is linked to a polyglutamine expansion mutation in the androgen receptor (AR). In mouse models of SBMA, motor dysfunction is associated with pronounced defects in neuromuscular transmission, including defects in evoked transmitter release (quantal content, QC) and fiber membrane excitability (based on the resting membrane potential, RMP). However, whether such defects are androgen-dependent is unknown. Thus, we recorded synaptic potentials intracellularly from adult muscle fibers of transgenic (Tg) AR97Q male mice castrated pre-symptomatically. Although castration largely protects both QC and the RMP of fibers, correlating with the protective effect of castration on motor function, significant deficits in QC and RMP remained. Surprisingly, comparable defects in QC and RMP were also observed in pre-symptomatic AR97Q males, indicating that such defects emerge early and are pre-clinical. Exposing asymptomatic Tg females to androgens also induces both motor dysfunction and comparable defects in QC and RMP. Notably, asymptomatic Tg females also showed significant deficits in QC and RMP, albeit less severe, supporting their pre-clinical nature, but also raising questions about the androgen-dependence of pre-clinical symptoms. In summary, current evidence indicates that disease progression depends on androgens, but early pathogenic events may be triggered by the mutant AR allele independent of androgens. Such early, androgen-independent disease mechanisms may also be relevant to females carrying the SBMA allele.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29897452      PMCID: PMC6030880          DOI: 10.1093/hmg/ddy142

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  54 in total

Review 1.  Ion channels and ion transporters of the transverse tubular system of skeletal muscle.

Authors:  Karin Jurkat-Rott; Michael Fauler; Frank Lehmann-Horn
Journal:  J Muscle Res Cell Motil       Date:  2006-08-24       Impact factor: 2.698

2.  The effect of membrane capacitance on non-linear summation of synaptic potentials.

Authors:  A R Martin
Journal:  J Theor Biol       Date:  1976-06       Impact factor: 2.691

3.  Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients.

Authors:  Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Masahiro Waza; Chen Sang; Yuji Nakagomi; Yasushi Kobayashi; Fumiaki Tanaka; Manabu Doyu; Akira Inukai; Mari Yoshida; Yoshio Hashizume; Gen Sobue
Journal:  Brain       Date:  2005-01-19       Impact factor: 13.501

Review 4.  Gonadal steroid induction of structural sex differences in the central nervous system.

Authors:  A P Arnold; R A Gorski
Journal:  Annu Rev Neurosci       Date:  1984       Impact factor: 12.449

5.  Regulation of transmitter release by synapsin II in mouse motor terminals.

Authors:  Dmitry Samigullin; Cynthia A Bill; William L Coleman; Maria Bykhovskaia
Journal:  J Physiol       Date:  2004-09-23       Impact factor: 5.182

Review 6.  Spinal and bulbar muscular atrophy: a motoneuron or muscle disease?

Authors:  Cynthia L Jordan; Andrew P Lieberman
Journal:  Curr Opin Pharmacol       Date:  2008-09-18       Impact factor: 5.547

7.  Involvement of 3Na+/2K+ ATP-ase and Pi-3 kinase in the response of skeletal muscle ATP-sensitive K+ channels to insulin.

Authors:  Domenico Tricarico; Loredana Montanari; Diana Conte Camerino
Journal:  Neuromuscul Disord       Date:  2003-11       Impact factor: 4.296

8.  Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies.

Authors:  Domenico Tricarico; Diana Conte Camerino
Journal:  Front Pharmacol       Date:  2011-02-28       Impact factor: 5.810

9.  Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females.

Authors:  Gianni Sorarù; Carla D'Ascenzo; Alberto Polo; Arianna Palmieri; Linda Baggio; Lodovica Vergani; Cinzia Gellera; Giuseppe Moretto; Elena Pegoraro; Corrado Angelini
Journal:  J Neurol Sci       Date:  2007-09-12       Impact factor: 3.181

Review 10.  Molecular Machines Regulating the Release Probability of Synaptic Vesicles at the Active Zone.

Authors:  Christoph Körber; Thomas Kuner
Journal:  Front Synaptic Neurosci       Date:  2016-03-02
View more
  4 in total

1.  Neuromuscular junction pathology is correlated with differential motor unit vulnerability in spinal and bulbar muscular atrophy.

Authors:  Elana Molotsky; Yuhong Liu; Andrew P Lieberman; Diane E Merry
Journal:  Acta Neuropathol Commun       Date:  2022-07-05       Impact factor: 7.578

Review 2.  The Regulation of the Small Heat Shock Protein B8 in Misfolding Protein Diseases Causing Motoneuronal and Muscle Cell Death.

Authors:  Riccardo Cristofani; Paola Rusmini; Mariarita Galbiati; Maria Elena Cicardi; Veronica Ferrari; Barbara Tedesco; Elena Casarotto; Marta Chierichetti; Elio Messi; Margherita Piccolella; Serena Carra; Valeria Crippa; Angelo Poletti
Journal:  Front Neurosci       Date:  2019-08-02       Impact factor: 4.677

3.  Autophagic and Proteasomal Mediated Removal of Mutant Androgen Receptor in Muscle Models of Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Elena Cicardi; Riccardo Cristofani; Valeria Crippa; Veronica Ferrari; Barbara Tedesco; Elena Casarotto; Marta Chierichetti; Mariarita Galbiati; Margherita Piccolella; Elio Messi; Serena Carra; Maria Pennuto; Paola Rusmini; Angelo Poletti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-20       Impact factor: 5.555

Review 4.  Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease.

Authors:  Frederick J Arnold; Diane E Merry
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.